519 filings
8-K
VVUS
Vivus Inc
16 Nov 20
VIVUS Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan of Reorganization and Existing Stock Record Date
6:08am
8-K
VVUS
Vivus Inc
13 Jul 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:31am
8-K
VVUS
Vivus Inc
7 Jul 20
Entry into a Material Definitive Agreement
5:27pm
8-K
VVUS
Vivus Inc
19 Jun 20
Regulation FD Disclosure
9:19am
8-K
VVUS
Vivus Inc
2 Jun 20
Entry into a Material Definitive Agreement
7:35am
8-K
bjy hm48mjc
8 May 20
VIVUS Q1 2020 Earnings Conference Call
4:45pm
8-K
zh11q9 7w3
6 May 20
VIVUS Reports First Quarter 2020 Financial Results
4:10pm
8-K
0ku6wbnd
1 May 20
VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt
8:30am
8-K
okywx j5a4xpajons3
3 Apr 20
VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
3:05pm
8-K
16pe 3z8ru7vd
2 Apr 20
Entry into a Material Definitive Agreement
5:28pm
8-K
mvtr61xbjqyf wnm3
1 Apr 20
VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:00pm
8-K
keri1h
31 Mar 20
Other Events
7:35am
8-K
fwq8103q5qv
6 Mar 20
VIVUS Q4 2019 Earnings Conference Call
4:05pm
8-K
p0zn7bnb4ohl1imw8yf
6 Mar 20
Entry into a Material Definitive Agreement
12:00am
8-K
u4vowa lpsq16bqw
3 Mar 20
VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results
4:10pm
8-K
js0kk0g
2 Mar 20
VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of
7:43am
8-K
bhixzcb1
21 Feb 20
Departure of Directors or Certain Officers
4:05pm
8-K
o7i5 zk6ugkg
19 Feb 20
VIVUS Announces Commercial Launch of Qsymia®in the Republic of Korea Establishing New Royalty Revenue Stream
7:35am
8-K
rw1o0
5 Feb 20
VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life
7:35am
8-K
l681 4nlidfwy9j
31 Jan 20
Departure of Directors or Certain Officers
4:35pm